MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support global Sandoz decarbonization efforts and sustainability commitment Basel, August 12, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its financial results for the first half of 2025. Growth in this document is shown at constant currencies (CC)[1] unless stated otherwise. FINANCIAL [...]
MEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 years Ongoing investment in in-house manufacturing to create end-to-end leading European biosimilar hub, capital expenditure commitments remain unchanged Most recent USD 440 million investment in new production plant in [...]
Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence and quality of life [1-10] Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10] Launch strengthens Sandoz biosimilar leadership position in immunology and commitment to patient-centric innovation [...]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in US up by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and 2024 divestment [...]
Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to develop and manufacture biosimilar, with Sandoz to register and commercialize after expiry of relevant patents across global markets Combination therapy of ipilimumab and nivolumab used in 95% of [...]
All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for re-election confirmed Dividend of CHF 0.60 per registered dividend-paying share approved, representing 24% of core net income Basel, April 15, 2025 (Korea Bizwire) – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals [...]
![[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US](http://koreabizwire.com/wp/wp-content/uploads/2024/01/Sandoz-Holzkirchen.png "[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US")
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseases Despite FDA approval nearly a decade ago, [...]
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidity New facility replaces initial and unutilized USD 1.25 billion RCF, in place since spin-off in 2023 Dual-tranche CHF 400m and single-tranche EUR 500 [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2.7 billion, up by 9% in constant currencies (+7% in USD) Strong sales performances in all three regions, driven [...]